Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax Obtains Approval for Provisional Registration of COVID-19 Vaccine in Australia

01/20/2022 | 04:40am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about NOVAVAX, INC.
05/20SECTOR UPDATE : Health Care Stocks Rebound In Final Hour of Friday Trade
MT
05/20SECTOR UPDATE : Health Care Stocks Beginning to Sputter Amid Broader Markets Slide
MT
05/20Novavax Shares Drop After BofA Securities Begins Coverage at Underperform
MT
05/20EMA Starts Evaluation of Booster Dose Usage of Novavax's COVID-19 Vaccine
MT
05/20EMA Starts Evaluating Use Of Booster Dose Of Nuvaxovid In Adults
RE
05/20BofA Securities Initiates Coverage on Novavax With Underperform Rating
MT
05/16Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
AQ
05/11TRANSCRIPT : Novavax, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
CI
05/11SECTOR UPDATE : Health Care Stocks Edging Lower Ahead of Wednesday Close
MT
05/11SECTOR UPDATE : Health Care Stocks Still Hanging on for Small Advance
MT
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 278 M - -
Net income 2022 1 941 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 2,26x
Yield 2022 -
Capitalization 4 174 M 4 174 M -
EV / Sales 2022 0,39x
EV / Sales 2023 0,26x
Nbr of Employees 1 541
Free-Float 99,0%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 53,42 $
Average target price 154,86 $
Spread / Average Target 190%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-62.66%4 174
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567